Taiwan Liposome Co (台灣微脂體) is expected to raise NT$591.36 million (US$20.31 million) from its initial public offering (IPO) on Friday next week, with the firm planning to use the proceeds to improve its gross margin and strengthen its bottom line.
The biopharmaceutical company, headquartered in Taipei’s Nangang Software Park (南港軟體園區), plans to issue 4.62 million new shares on its the GRETAI Securities Market debut and has tentatively set the IPO price at NT$128, the company said.
On Monday, Taiwan Liposome began book building for institutional investors after receiving regulatory approval. The book building, whereby institutional investors make bids for the stock on offer, ends on Thurday, the company said.
Taiwan Liposome currently trades on the smaller Emerging Stock Market, a preparatory board for the nation’s two main bourses. Its shares closed 1.64 percent higher yesterday at NT$279.50, rising 288.9 percent so far this year, according to stock exchange data.
The company reported a net income of NT$24.3 million, or earnings per share of NT$0.62, in the third quarter, after posting a net loss of NT$40.69 million, or a net loss per share of NT$1.04 per share, in the first half of the year.
In the first three quarters of the year, Taiwan Liposome posted a net loss of NT$16.34 million, or loss per share of NT$0.42, much lower than a net loss of NT$137.43 million, or NT$5.11 per share, a year earlier, company data showed.
During the first 11 months of the year, sales surged 210.7 percent to NT$233.195 million from NT$75.048 million a year ago, the company said on Monday.
Analysts say the company is likely to swing into profit next year on the back of certain milestone payments and royalties on product sales. Taiwan Liposome reported a net loss of NT$216.99 million last year, NT$190.21 million in 2010 and NT$184.07 million in 2009.
Established in 1997, Taiwan Liposome focuses on the research and development of pharmaceutical products based on its proprietary drug delivery technologies.
“Traditionally, drugs are transmitted via blood, and the amount of drugs that can reach infected organs is little,” Taiwan Liposome president George Yeh (葉志鴻) said at a pre-IPO conference for investors on Nov. 28.
“We use lipid-based formulation that delivers the drug to infected body parts and releases the drug there, creating better efficacy and lower toxicity for the drugs,” Yeh said.
Lipid-based formulations can also be used to control the amount of drugs released in a given period of time, prolonging the product lifecycle of drugs.
In the past few years, Taiwan Liposome has developed drugs used to treat breast cancer and ovarian cancer, such as Lipo-Dox and Doxisome, as well as ProFlow, a drug used to treat peripheral vascular disease. The company is expected to invest NT$1.15 billion into new drug development from this year through 2016.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained